Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist.
about
Sphingosine-1-Phosphate Receptor-3 Supports Hematopoietic Stem and Progenitor Cell Residence Within the Bone Marrow Niche.Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury.Delivery of S1P receptor-targeted drugs via biodegradable polymer scaffolds enhances bone regeneration in a critical size cranial defect.Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesisDesign, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate.Characterization of a sphingosine 1-phosphate receptor antagonist prodrugSphingosine 1-phosphate chemical biologySelective activation of sphingosine 1-phosphate receptors 1 and 3 promotes local microvascular network growthInternational Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitorsSphingosine-1-phosphate receptors: biology and therapeutic potential in kidney diseaseSphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype.Pulmonary endothelial cell barrier enhancement by novel FTY720 analogs: methoxy-FTY720, fluoro-FTY720, and β-glucuronide-FTY720.Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury.Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro.Development of small-molecule therapies for autoimmune diseases.Sphingosine lysolipids in the CNS: endogenous cannabinoid antagonists or a parallel pain modulatory system?Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo.Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.Design and synthesis of pyrrolidine-containing sphingomimetics.Enantioselective Heck-Matsuda Arylations through Chiral Anion Phase-Transfer of Aryl Diazonium Salts.Evaluation and Optimization of in silico designed Sphingosine-1-Phosphate (S1P) Receptor Subtype 1 Modulators for the Management of Multiple Sclerosis.Enantioselective total synthesis of the highly selective sphingosine-1-receptor VPC01091 by the Heck desymmetrization of a non-activated cyclopentene-fused spiro-pyrrolidinone.Novel Lipid Signaling Mediators for Mesenchymal Stem Cell Mobilization during Bone Repair
P2860
Q30275148-6BB96261-E252-45D3-BE90-640CD8540B2EQ30300119-DBDE57C5-C908-461F-AB50-21CEF7A5E4B5Q30406089-7548AA23-E42D-443E-954F-486D8BFA725EQ30410634-1E51188B-676F-4AE8-9595-FD38F7396D92Q30417313-B2CCB664-A4D8-41CE-B4BE-1C61E1053F66Q30417604-25D2D517-02BF-4AA9-8E78-36FEAA8C312EQ30423337-169C9143-067A-4FFD-A4A6-E1E9B06AB6DDQ30425227-F0E653AF-03CE-4DF4-83BD-1020BB3F8EA1Q30425603-902CAB40-725D-4A7D-BBCF-CC413E388FA2Q30428199-C7F90127-C8FF-4FA6-AC0D-47FF66F5F906Q30429523-D50E35B0-BBA2-4115-A507-054C5FA98F67Q30432733-B25D1BA1-7194-4F40-AD4B-C8EFE2E8F28EQ30440476-61DAF268-28ED-495B-8ED4-C542D1C171D4Q30440617-97C9E52A-F9AE-41D9-A438-DB1AA3C8F80CQ36306831-A73F5EAE-A0FF-46B2-AABB-93716635EFBDQ37056490-E90E15AD-DF5A-4804-95D2-E9F56244DB4DQ37327927-91E63EDB-044A-4688-BB22-1063EEC3D4B6Q37397209-DC4375B0-9695-47EA-978E-1D7FB78BDDFCQ37730104-68237FA7-1772-47D5-B643-0D6D75E151DCQ38115668-CF71D32F-2A69-494A-B9B4-CA4C3ECF13D5Q38812925-B37183DF-3D3B-48DE-BFCD-DAD36FB7C2FFQ38966334-9855366A-CA34-4BDB-B6F9-D831CE8C834CQ39549539-6B9FBA27-5FCC-4F9F-87CC-BA81CDCBB498Q41136749-6AAC568A-60BE-44F1-B697-445ACA9E66DCQ42371801-3E9B7302-45DF-452C-8525-266ADABE85E5Q48310639-46336A46-5CAA-4B34-9FE3-51491210B2D8Q56334654-B69B1DEB-4B61-4FA6-BF65-84FCEAF940AF
P2860
Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Asymmetric synthesis of confor ...... nd receptor type-3 antagonist.
@ast
Asymmetric synthesis of confor ...... nd receptor type-3 antagonist.
@en
type
label
Asymmetric synthesis of confor ...... nd receptor type-3 antagonist.
@ast
Asymmetric synthesis of confor ...... nd receptor type-3 antagonist.
@en
prefLabel
Asymmetric synthesis of confor ...... nd receptor type-3 antagonist.
@ast
Asymmetric synthesis of confor ...... nd receptor type-3 antagonist.
@en
P2093
P2860
P356
P1476
Asymmetric synthesis of confor ...... nd receptor type-3 antagonist.
@en
P2093
Ashley H Snyder
Kevin R Lynch
Lisa Schaffter
Perry C Kennedy
Timothy L Macdonald
Yugesh Kharel
P2860
P304
P356
10.1021/JM7010172
P407
P577
2007-11-10T00:00:00Z